Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucrictibant for on-demand treatment of hereditary angioedema attacks
NCT06343779Phase 3Completed
- Sponsor
- Pharvaris
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Started Feb 2024; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06343779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343779.